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Letter to the Editor
What should we consider in 
mixed chimerism after hemato-
poietic stem cell transplanta-
tion?
TO THE EDITOR: Mixed chimerism (MC) was initially 
thought to indicate impending relapse; however, it has be-
come clear that it is an important parameter for estimating 
immunologic balance after hematopoietic stem cell trans-
plantation (HSCT). Moreover, the emergence of more tail-
ored HSCT procedures, including reduced-intensity stem 
cell transplantation (RIST), depletion of the donor’s T cells 
from bone marrow graft, and donor lymphocyte infusion 
(DLI), makes it even more important to estimate the exact 
chimeric status after HSCT. 
 Recently, Goh et al. reported MC results in 24 myeloa-
blative HSCT patients. MC in nucleated cells (NCs) was 
significantly correlated with relapse, and MC in NCs, T 
cells, and NK cells was correlated with mortality. Further-
more, MC in all cell types was uncorrelated with the in-
cidence of acute and chronic graft-versus-host disease 
(GVHD). These data were analyzed in limited cases, but 
individual diseases and HSCT strategy were not considered 
[1]. 
 Myeloablative HSCT without T cell depletion often results 
i n  G V H D  b u t  i s  a s s o c i a t e d  w i t h  l e s s  f r e q u e n t  r e l a p s e .  T  
cells in the graft lead to full donor complete chimerism 
(CC), although early CC indicates GVHD. However, T 
cell-depleted (TCD) myeloablative HSCT is commonly 
found to give rise to MC, and is therefore used to avoid 
GVHD. In the case of RICT, all cases typically experience 
MC. Therefore, MC has to be precisely evaluated. Low donor 
T cell and NK cell chimerism levels around the second 
week after HSCT are associated with high probabilities of 
graft rejection, whereas early establishment of donor NK 
cell chimerism is associated with better progression-free 
survival [2]. In contrast to NK cell chimerism, early estab-
lishment of donor T cell chimerism is associated with the 
development of acute GVHD [3]. In recent interesting re-
ports on lineage-specific chimerism, monitoring of leukemia 
lineage-specific chimerism has been shown to be important 
for DLI response in the case of relapse after HSCT [4]. 
Further, a low donor T cell chimerism of ＜60% at day 
30 may be associated with a poor prognosis in HSCT when 
using a busulfan-containing reduced-intensity conditioning 
regimen [5]. Although MC is an important indicator of 
disease relapse, graft rejection, or GVHD post HSCT, it 
should be taken into consideration that the recipient cells 
in MC could be normal hematopoietic cells or leukemic 
cells. Therefore, it is important to identify those patients 
who develop an increasing or progressive MC of recipient 
cells by monitoring serial chimerism levels. Additionally, 
with respect to accurate analysis of chimerism, it should 
be recognized that variation in the degree of MC is influ-
enced by a number of factors, including the sensitivity of 
the method used, the timing of the assay, the disease in-
dication for HSCT, the stage of disease at the time of HSCT, 
and the choice of conditioning regimen.
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